<DOC>
	<DOC>NCT00121069</DOC>
	<brief_summary>This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.</brief_summary>
	<brief_title>Study of Escitalopram in the Treatment of Specific Phobia</brief_title>
	<detailed_description>This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.</detailed_description>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Adults 1865 years of age DSMIV criteria for specific phobia according to the MINI For women of childbearing potential, a negative serum pregnancy test at screening Written informed consent Any current primary DSMIV diagnosis other than specific phobia History of DSMIV substance abuse or dependence within the last months Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition Suicide risk or serious suicide attempt within the last year Clinically significant laboratory or EKG abnormality or unstable medical condition For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study Subjects needing concurrent use of psychotropic medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>specific phobia</keyword>
	<keyword>anxiety</keyword>
	<keyword>SSRI</keyword>
	<keyword>clinical trial</keyword>
	<keyword>escitalopram</keyword>
</DOC>